Savara Announces Closing Of Merger With Mast Therapeutics Apr 28, 2017 02:01PM
Savara Announces Closing Of Merger With Mast Therapeutics Apr 27, 2017 04:15PM
Notable Mergers and Acquisitions 11/21: (SXL)/(ETP) (ORCL) (MSTX) (MTSI)/(AMCC) Nov 21, 2016 09:48AM
Mast Therapeutics (MSTX) Announces Joining Sickle Cell Disease Coalition Sep 6, 2016 08:07AM
Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care Sep 6, 2016 08:00AM
View Older Stories

Sep 6, 2016 08:00AM Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care
Sep 1, 2016 08:00AM Mast Therapeutics To Present At 18th Annual Rodman & Renshaw Global Investment Conference On September 13th
Sep 1, 2016 08:00AM Mast Therapeutics To Present At 18th Annual Rodman & Renshaw Global Investment Conference On September 13th
Aug 9, 2016 08:00AM Mast Therapeutics Reports Second Quarter 2016 Financial Results
Aug 8, 2016 08:00AM Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health
Aug 3, 2016 08:00AM Mast Therapeutics Announces Issuance Of Composition Of Matter Patent Covering Vepoloxamer
Aug 2, 2016 08:00AM Mast Therapeutics To Present At 36th Annual Canaccord Genuity Growth Conference On August 10
Aug 1, 2016 08:00AM Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network
Jun 8, 2016 04:08PM Mast Therapeutics (MSTX) Receives USPTO Notice Of Allowance for Vepoloxamer-Related Patent
Jun 8, 2016 04:05PM Mast Therapeutics Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer
May 23, 2016 08:00AM Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure
May 16, 2016 08:08AM Mast Therapeutics (MSTX) Reports Positive Interim Results From Second Phase 2a Study of AIR001 in Patients With HFpEF
May 16, 2016 08:00AM Positive Interim Results From Second Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Presented At American Thoracic Society International Conference
May 6, 2016 08:00AM Mast Therapeutics Reports First Quarter 2016 Financial Results And Recent Highlights
Apr 13, 2016 08:10AM Mast Therapeutics (MSTX) Unit Enters Agreement with Duke University for AIR001 Phase 2
Apr 13, 2016 08:00AM Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network
Apr 4, 2016 08:00AM Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo
Mar 14, 2016 08:00AM Mast Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results
Mar 1, 2016 08:00AM Mast Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference On March 7th
Feb 29, 2016 08:00AM Mast Announces Amendment To Loan And Security Agreement With Hercules Capital
Feb 22, 2016 06:24AM Mast Therapeutics (MSTX) Announces Completion of Vepoloxamer Phase 3 Enrollment
Feb 22, 2016 05:00AM Mast Therapeutics Completes Patient Enrollment In Pivotal Phase 3 "EPIC" Study For The Treatment Of Sickle Cell Crisis
Feb 16, 2016 04:15PM Mast Therapeutics Closes $8 Million Public Offering
Feb 10, 2016 09:24AM Mast Therapeutics (MSTX) Prices 29M Offering of Common Stock and Warrants at $0.275/Unit
Feb 10, 2016 09:09AM Mast Therapeutics Announces Pricing Of Underwritten Public Offering
Feb 9, 2016 05:31PM Mast Therapeutics (MSTX) to Offer Common Stock And Warrants
Feb 9, 2016 04:23PM Mast Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants
Feb 2, 2016 08:00AM Mast Therapeutics To Present At 2016 BIO CEO & Investor Conference On February 8th
Feb 1, 2016 09:19AM Pre-Open Stock Movers 02/01: (ALR) (STR) (TROV) Higher; (GPRO) (TSLA) (D) Lower (more...)
Feb 1, 2016 09:10AM Mast Therapeutics' AIR001 Selected By The Heart Failure Clinical Research Network For Evaluation In A 100-Patient Multicenter Phase 2 Study
Feb 1, 2016 07:34AM Mast Therapeutics (MSTX) Announces Statistically Significant Top-Line Data from AIR001 Phase 2a in HFpEF
Feb 1, 2016 07:30AM Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic
Jan 7, 2016 08:06AM Mast Therapeutics (MSTX) Offers Business Update; Phase 3 EPIC Enrollment Surpasses 90% Mark
Jan 7, 2016 08:00AM Mast Therapeutics Provides Business Update
Nov 24, 2015 08:00AM Mast Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference
Nov 16, 2015 08:00AM Vepoloxamer Data Selected For Presentation At 57th Annual American Society Of Hematology (ASH) Meeting
Nov 12, 2015 04:05PM Mast Therapeutics Reports Third Quarter 2015 Financial Results
Nov 9, 2015 08:15AM Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions
Nov 9, 2015 08:00AM Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors
Nov 2, 2015 08:00AM Mast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors
Oct 29, 2015 08:00AM Mast Therapeutics To Host Third Quarter 2015 Financial Results And Corporate Update Conference Call
Oct 26, 2015 08:00AM Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure
Oct 13, 2015 08:00AM BASF to Develop a High Purity Poloxamer for Mast Therapeutics
Oct 5, 2015 02:28PM Mast Therapeutics (MSTX) Plans to Hold First-Ever Investor Day
Sep 30, 2015 08:00AM Mast Announces Amendment To Loan And Security Agreement With Hercules Technology Growth Capital
Sep 28, 2015 08:00AM Mast Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting
Sep 23, 2015 08:00AM Mast Therapeutics To Host Analyst & Investor Day On October 7, 2015
Aug 12, 2015 04:05PM Mast Therapeutics Reports Second Quarter 2015 Financial Results
Aug 6, 2015 08:00AM Mast Therapeutics To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call
May 28, 2015 04:30PM Mast Therapeutics Announces Change In Board Of Directors
View Older Stories